Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
Orchestra BioMed (Nasdaq: OBIO), a biomedical company specializing in high-impact technologies through risk-reward sharing partnerships, announced its participation in the Jefferies Global Healthcare Conference.
The event will take place in New York, NY, from June 4-6, 2024. Company management will present at a fireside chat on June 5 at 4:00 PM ET.
The presentation will be webcast and available on the company's website for 90 days.
- Orchestra BioMed's participation in the Jefferies Global Healthcare Conference enhances visibility within the investment community.
- The presentation format as a fireside chat allows for in-depth discussion about the company's strategies and technologies.
- Availability of the webcast for 90 days provides ongoing access to the company's strategic insights for a wider audience.
- The press release lacks specific financial or clinical data updates that investors often look for.
- No new partnerships or technological advancements were announced, which may disappoint those seeking concrete developments.
- The stock price impact is uncertain as the PR mainly emphasizes the company's participation in a conference without immediate business results.
NEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 4-6, 2024.
Details of the presentation are below.
Format: Fireside Chat
Date: Wednesday, June 5, 2024
Time: 4:00 PM ET (Track 1)
Webcast: https://wsw.com/webcast/jeff302/obio/1835536
A replay of the webcast will be available on the Events section of the Orchestra BioMed website for 90 days following the presentation.
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Bob Yedid
LifeSci Advisors
516-428-8577
Bob@lifesciadvisors.com
Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
484-682-4892
Kkirkellis@orchestrabiomed.com
![](https://ml.globenewswire.com/media/ZTEyNmViYmMtOWM2Yy00ODFiLWIwMmYtYmVmMjNhMTQ4Y2I3LTEyMDU1NzI=/tiny/Orchestra-BioMed-Holdings-Inc-.png)
FAQ
What is Orchestra BioMed's stock symbol?
When will Orchestra BioMed present at the Jefferies Global Healthcare Conference?
Where is the Jefferies Global Healthcare Conference held?
How can I access the webcast of Orchestra BioMed's presentation?